Discovery and development of biomarkers of neurological disease

被引:60
作者
Dunckley, T [1 ]
Coon, KD [1 ]
Stephan, DA [1 ]
机构
[1] Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ 85004 USA
关键词
D O I
10.1016/S1359-6446(04)03353-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The identification of clinically relevant biomarkers for neurological diseases poses unique challenges. These include an historical lack of availability of relevant tissues from the site of pathology, relatively poorly matured techniques for disease diagnosis, the complexity and cellular heterogeneity of the brain, and a clear deficiency of models for functional validation of candidate biomarkers. Here, the unique challenges that neurological disorders introduce to biomarker discovery are described and how modern technological advances in genomics, proteornics and metabolomics are overcoming these obstacles and are driving the discovery of novel biomarkers to improve early diagnosis and therapeutic treatment is discussed.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 85 条
[1]   Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank [J].
Barker, WW ;
Luis, CA ;
Kashuba, A ;
Luis, M ;
Harwood, DG ;
Loewenstein, D ;
Waters, C ;
Jimison, P ;
Shepherd, E ;
Sevush, S ;
Graff-Radford, N ;
Newland, D ;
Todd, M ;
Miller, B ;
Gold, M ;
Heilman, K ;
Doty, L ;
Goodman, I ;
Robinson, B ;
Pearl, G ;
Dickson, D ;
Duara, R .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 (04) :203-212
[2]   LOCALIZATION OF XP21 MEIOTIC EXCHANGE POINTS IN DUCHENNE MUSCULAR-DYSTROPHY FAMILIES [J].
BERTELSON, CJ ;
BARTLEY, JA ;
MONACO, AP ;
COLLETTIFEENER, C ;
FISCHBECK, K ;
KUNKEL, LM .
JOURNAL OF MEDICAL GENETICS, 1986, 23 (06) :531-537
[3]   Gene expression profile in multiple sclerosis patients and healthy controls:: identifying pathways relevant to disease [J].
Bomprezzi, R ;
Ringnér, M ;
Kim, S ;
Bittner, ML ;
Khan, J ;
Chen, YD ;
Elkahloun, A ;
Yu, AM ;
Bielekova, B ;
Meltzer, PS ;
Martin, R ;
McFarland, HF ;
Trent, JM .
HUMAN MOLECULAR GENETICS, 2003, 12 (17) :2191-2199
[4]   Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins [J].
Borchelt, DR ;
Ratovitski, T ;
vanLare, J ;
Lee, MK ;
Gonzales, V ;
Jenkins, NA ;
Copeland, NG ;
Price, DL ;
Sisodia, SS .
NEURON, 1997, 19 (04) :939-945
[5]   Familial Alzheimer's disease-linked presenilin 1 variants elevate A beta 1-42/1-40 ratio in vitro and in vivo [J].
Borchelt, DR ;
Thinakaran, G ;
Eckman, CB ;
Lee, MK ;
Davenport, F ;
Ratovitsky, T ;
Prada, CM ;
Kim, G ;
Seekins, S ;
Yager, D ;
Slunt, HH ;
Wang, R ;
Seeger, M ;
Levey, AI ;
Gandy, SE ;
Copeland, NG ;
Jenkins, NA ;
Price, DL ;
Younkin, SG .
NEURON, 1996, 17 (05) :1005-1013
[6]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[7]   Quantitation of neuropeptides in Cpefat/Cpefat mice using differential isotopic tags and mass spectrometry [J].
Che, FY ;
Fricker, LD .
ANALYTICAL CHEMISTRY, 2002, 74 (13) :3190-3198
[8]   Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation [J].
Chui, DH ;
Tanahashi, H ;
Ozawa, K ;
Ikeda, S ;
Checler, F ;
Ueda, O ;
Suzuki, H ;
Araki, W ;
Inoue, H ;
Shirotani, K ;
Takahashi, K ;
Gallyas, F ;
Tabira, T .
NATURE MEDICINE, 1999, 5 (05) :560-564
[9]  
CHUI H, 2001, CLIN CRITERIA VARIOU
[10]   Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [J].
Citron, M ;
Westaway, D ;
Xia, WM ;
Carlson, G ;
Diehl, T ;
Levesque, G ;
JohnsonWood, K ;
Lee, M ;
Seubert, P ;
Davis, A ;
Kholodenko, D ;
Motter, R ;
Sherrington, R ;
Perry, B ;
Yao, H ;
Strome, R ;
Lieberburg, I ;
Rommens, J ;
Kim, S ;
Schenk, D ;
Fraser, P ;
Hyslop, PS ;
Selkoe, DJ .
NATURE MEDICINE, 1997, 3 (01) :67-72